Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model1

Journal of Pharmacology and Experimental Therapeutics

Volumn 295, Issue 2, 2000, Pages 492-499

  Huang, J ^a   Driscoll, E M ^a   Gonzales, M L ^a   Park, A M ^a   Lucchesi, B R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 N METHYLADENOSINE; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; AR C69931 MX; CLODRONIC ACID; N 6 [(2 METHYLTHIO)ETHYL] 2 (3,3,3 TRIFLUOROPROPYL) 5' ADENYLIC ACID; PLACEBO; THROMBOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY OCCLUSION; ARTERY THROMBOSIS; ARTICLE; BLEEDING TIME; CAROTID ARTERY FLOW; CONTROLLED STUDY; DOG; DRUG MECHANISM; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADENOSINE DIPHOSPHATE; ADENOSINE MONOPHOSPHATE; ANIMAL; ARTERIAL OCCLUSIVE DISEASES; BLEEDING TIME; BLOOD FLOW VELOCITY; BLOOD PLATELETS; CAROTID ARTERIES; CAROTID ARTERY THROMBOSIS; COMPARATIVE STUDY; DISEASE MODELS, ANIMAL; DOGS; FEMALE; HEMODYNAMICS; INJECTIONS, INTRAVENOUS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2; SUPPORT, NON-U.S. GOV'T; TUNICA INTIMA;

EID: 0033781969     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Platelet/vessel wall interactions, rheologic factors and thrombogenic substrate in acute coronary syndromes: Preventive strategies
2. Sustained inhibition of the vessel wall-platelet interaction after deep coronary artery injury by temporary inhibition of the platelet glycoprotein IIb/IIIa receptor
3. Quantitative investigations into the aggregation of blood platelets
4. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors
5. Adenosine 5'-diphosphate antagonists and human platelets: No evidence that aggregation and inhibition of stimulated adenylate cyclase are mediated by different receptors
6. Specific but noncompetitive inhibition by 2-alkylthio analogues of adenosine 5'-monophosphate and adenosine 5'-triphosphate of human platelet aggregation induced by adenosine 5'-diphosphate
7. Differential inhibition by adenosine or by prostaglandin E1 of human platelet aggregation induced by adenosine 5'-O-(1-thiodiphosphate) and adenosine 5'-O-(2-thiodiphosphate)
8. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets
9. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets
10. Influence of the ADP antagonists AR-C67085 and A2P5P on ADP-induced responses of platelets and isolated arteries
11. Extracellular ATP: Effects, sources and fate
12. Development of nonthrombogenicity of injured rabbit aortas despite inhibition of platelet adherence
13. Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets
14. 2-MeS-AMP-PCP and human platelets: Implications for the role of adenylate cyclase in ADP-induced aggregation?
15. Pharmacological profile of the novel P2T-purinoceptor antagonist, FPL 67085 in vitro and in the anaesthetized rat in vivo
16. The P2T-purinoceptor antagonist, FPL 67085, is a potent, efficacious and selective inhibitor of dynamic arterial thrombosis in the pentobarbitone-aneaesthetized dog
17. Antagonists of the platelet P2T receptor: A novel approach to antithrombotic therapy
18. Co-activation of P2Y1 and P2TAC receptors and subsequent platelet aggregation are essential for ADP-induced thromboxane A2 generation in human platelets
19. P1- and P2-purinoceptor subtypes - An update
20. The role of ADP in thrombosis and the therapeutic potential of P2T-receptor antagonists as novel antithrombotic agents
21. Platelets from P2Y, receptor knockout mice do not aggregate in response to ADP
22. The effects of ATP on platelets: Evidence against the central role of released ADP in primary aggregation
23. Antiplatelet monoclonal F(ab')2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart
24. Investigation of the novel P2T receptor antagonist AR-C69931MX on ex vivo adenosine diphosphate-induced platelet aggregation and bleeding time in healthy volunteers
25. Molecular mechanism of thromboxane A(2)-induced platelet aggregation. Essential role for P2T(ac) and alpha(2a) receptors
26. Ectonucleotidases: Measurement of activities and use of inhibitors
27. Electrical induction of coronary artery thrombosis in the ambulatory canine: A model for in vivo evaluation of anti-thrombotic agents
28. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties
29. ATP analogues and the guinea-pig Taenia coli: A comparison of the structure-activity relationships of ectonucleotidases with those of P2-purinoceptor